Restricted accessResearch articleFirst published online 2019-2
Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1
Several broadly neutralizing antibodies (bNAbs) that can target HIV strains with large degrees of variability have recently been identified. However, efforts to induce synthesis of such bNAbs that can protect against HIV infection have not met with much success. Identification of specific epitopes encoded in the HIV-1 envelope (Env) that can direct the host to synthesize bNAbs remains a challenge. In a previous study, we identified 12 antiretroviral therapy-naive HIV-1-infected individuals whose plasma exhibited broad cross-clade neutralization property against different clades of HIV-1. In this study, we sequenced the full-length HIV-1 gp160 from 11 of these individuals and analyzed the sequences to identify bNAb epitopes. We identified critical residues in the viral envelopes that contribute to the formation of conformational epitopes and possibly induce the production of bNAbs, using in silico methods. We found that many of the sequences had conserved glycans at positions N160 (10/11) and N332 (9/11), which are known to be critical for the binding of PG9/PG16-like and PGT128-like bNAbs, respectively. We also observed conservation of critical glycans at positions N234 and N276 critical for the interaction with CD4 binding site bNAbs in 8/11 and 11/11 sequences, respectively. We modeled the three-dimensional structure of the 11 HIV-1 envelopes and found that though each had structural differences, the critical residues were mostly present on the surface of the Env structures. The identified critical residues are proposed as candidates for further evaluation as bNAb epitopes.
Get full access to this article
View all access options for this article.
References
1.
SilvestriG: Embracing the complexity of HIV immunology. Immunol Rev, 2013; 254:5–9.
2.
LeeJH, LeamanDP, KimAS, et al.: Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nat Commun, 2015; 6:8167.
3.
BurtonDR, HangartnerL: Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol, 2016; 34:635–659.
4.
ShcherbakovDN, BakulinaAY, KarpenkoLI, IlyichevAA: Broadly neutralizing antibodies against HIV-1 As a novel aspect of the immune response. Acta Nat, 2015; 7:11–21.
5.
BarKJ, SnellerMC, HarrisonLJ, et al.: Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med, 2016; 375:2037–2050.
6.
CaskeyM, KleinF, LorenziJC, et al.: Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature, 2016; 535:580.
7.
KhanL, MakhdoomiMA, KumarS, et al.: Identification of CD4-binding site dependent plasma neutralizing antibodies in an HIV-1 infected Indian individual. PLoS One, 2015; 10:e0125575.
8.
PatilS, KumarR, DeshpandeS, et al.: Conformational epitope-specific broadly neutralizing plasma antibodies obtained from an HIV-1 clade C-infected elite neutralizer mediate autologous virus escape through mutations in the V1 loop. J Virol, 2016; 90:3446–3457.
9.
CheedarlaN, PrecillaKL, BabuH, et al.: Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals. Sci Rep, 2017; 7:46557.
10.
PonomarenkoJ, BuiHH, LiW, et al.: ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics, 2008; 9:514.
11.
KringelumJV, LundegaardC, LundO, NielsenM: Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol, 2012; 8:e1002829.
12.
Salazar-GonzalezJF, BailesE, PhamKT, et al.: Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol, 2008; 82:3952–3970.
13.
AshokkumarM, NesakumarM, CheedarlaN, et al.: Molecular characteristics of the envelope of vertically transmitted HIV-1 strains from infants with HIV infection. AIDS Res Hum Retroviruses, 2017; 33:796–806.
14.
BiasiniM, BienertS, WaterhouseA, et al.: SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res, 2014; 42:W252–W258.
15.
LovellSC, DavisIW, ArendallWB3rd, et al.: Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins, 2003; 50:437–450.
16.
WibmerCK, MoorePL, MorrisL: HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS, 2015; 10:135–143.
17.
HeL, de ValN, MorrisCD, et al.: Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat Commun, 2016; 7:12041.
18.
LiM, GaoF, MascolaJR, et al.: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol, 2005; 79:10108–10125.
19.
FalkowskaE, RamosA, FengY, et al.: PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol, 2012; 86:4394–4403.
20.
WestAPJr., ScharfL, ScheidJF, KleinF, BjorkmanPJ, NussenzweigMC: Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell, 2014; 156:633–648.
21.
HaynesBF, KelsoeG, HarrisonSC, KeplerTB: B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol, 2012; 30:423–433.
22.
LiaoHX, LynchR, ZhouT, et al.: Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 2013; 496:469–476.
23.
Doria-RoseNA, LouderMK, YangZ, et al.: HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J Virol, 2012; 86:3393–3397.
24.
WalkerLM, HuberM, DooresKJ, et al.: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature, 2011; 477:466–470.
25.
PejchalR, DooresKJ, WalkerLM, et al.: A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science, 2011; 334:1097–1103.
26.
HemelaarJ, GouwsE, GhysPD, OsmanovS; WHO-UNAIDS Network for HIV Isolation and Characterisation: Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS, 2011; 25:679–689.
27.
ChoudhuryS, MontanoMA, WomackC, et al.: Increased promoter diversity reveals a complex phylogeny of human immunodeficiency virus type 1 subtype C in India. J Hum Virol, 2000; 3:35–43.
28.
EshlemanSH, HudelsonSE, GuptaA, et al.: Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, India. AIDS Res Hum Retroviruses, 2005; 21:93–97.
29.
BalakrishnanP, KumarasamyN, KantorR, et al.: HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses, 2005; 21:301–305.
30.
MandalD, JanaS, PandaS, et al.: Distribution of HIV-1 subtypes in female sex workers of Calcutta, India. Indian J Med Res, 2000; 112:165–172.
31.
TripathyS, RenjifoB, WangWK, et al.: Envelope glycoprotein 120 sequences of primary HIV type 1 isolates from Pune and New Delhi, India. AIDS Res Hum Retroviruses, 1996; 12:1199–1202.
32.
SahniAK, PrasadVV, SethP: Genomic diversity of human immunodeficiency virus type-1 in India. Int J STD AIDS, 2002; 13:115–118.
33.
HemelaarJ, GouwsE, GhysPD, OsmanovS: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS, 2006; 20:W13–W23.
34.
JameelS, ZafrullahM, AhmadM, KapoorGS, SehgalS: A genetic analysis of HIV-1 from Punjab, India reveals the presence of multiple variants. AIDS, 1995; 9:685–690.
35.
GadkariDA, MooreD, SheppardHW, KulkarniSS, MehendaleSM, BollingerRC: Transmission of genetically diverse strains of HIV-1 in Pune, India. Indian J Med Res, 1998; 107:1–9.
36.
SiddappaNB, DashPK, MahadevanA, et al.: Identification of subtype C human immunodeficiency virus type 1 by subtype-specific PCR and its use in the characterization of viruses circulating in the southern parts of India. J Clin Microbiol, 2004; 42:2742–2751.
37.
DeshpandeA, JauvinV, PinsonP, JeannotAC, FleuryHJ: Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. AIDS Res Hum Retroviruses, 2009; 25:633–635.
38.
SarkarR, SarkarK, Brajachand SinghN, Manihar SinghY, MitraD, ChakrabartiS: Emergence of a unique recombinant form of HIV-1 from Manipur (India). J Clin Virol, 2012; 55:274–277.
39.
SarkarR, SarkarK, SinghNB, SinghYM, ChakrabartiS: Near full-length genomic characterization of a HIV type 1 BC recombinant strain from Manipur, India. Virus Genes, 2012; 45:201–206.
40.
PandeyS, TripathyS, ParanjapeR: Molecular characterization of unique intersubtype HIV type 1 A1/C recombinant strain circulating in Pune, India. AIDS Res Hum Retroviruses, 2013; 29:1245–1253.
41.
KorberB, GaschenB, YusimK, ThakallapallyR, KesmirC, DetoursV: Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull, 2001; 58:19–42.
42.
KongL, LeeJH, DooresKJ, et al.: Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol, 2013; 20:796–803.
43.
ChoeH, FarzanM, SunY, et al.: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell, 1996; 85:1135–1148.
44.
CormierEG, DragicT: The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol, 2002; 76:8953–8957.
45.
BisconeMJ, MiamidianJL, MuchiriJM, et al.: Functional impact of HIV coreceptor-binding site mutations. Virology, 2006; 351:226–236.
46.
NolanKM, JordanAP, HoxieJA: Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors. J Virol, 2008; 82:664–673.
47.
SaundersCJ, McCaffreyRA, ZharkikhI, et al.: The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol, 2005; 79:9069–9080.
48.
Zolla-PaznerS: Improving on nature: focusing the immune response on the V3 loop. Hum Antibodies, 2005; 14:69–72.
49.
TomarasGD, YatesNL, LiuP, et al.: Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol, 2008; 82:12449–12463.
50.
DavisKL, Bibollet-RucheF, LiH, et al.: Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol, 2009; 83:1240–1259.
51.
GornyMK, WilliamsC, VolskyB, et al.: Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol, 2002; 76:9035–9045.
52.
GornyMK, WilliamsC, VolskyB, et al.: Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J Virol, 2006; 80:6865–6872.
53.
SantraS, TomarasGD, WarrierR, et al.: Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. PLoS Pathog, 2015; 11:e1005042.
54.
HuangJ, OfekG, LaubL, et al.: Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature, 2012; 491:406–412.
55.
GachJS, LeamanDP, ZwickMB: Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. Curr Top Med Chem, 2011; 11:2997–3021.
McMichaelAJ, BorrowP, TomarasGD, GoonetillekeN, HaynesBF: The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol, 2010; 10:11–23.
58.
SatherDN, ArmannJ, ChingLK, et al.: Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol, 2009; 83:757–769.
59.
ShenX, ParksRJ, MontefioriDC, et al.: In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol, 2009; 83:3617–3625.
60.
JulienJP, SokD, KhayatR, et al.: Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog, 2013; 9:e1003342.
61.
de TaeyeSW, MooreJP, SandersRW: HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies. Trends Immunol, 2016; 37:221–232.
62.
BurtonDR, MascolaJR: Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol, 2015; 16:571–576.
63.
SuB, MoogC: Which antibody functions are important for an HIV vaccine?. Front Immunol, 2014; 5:289.
64.
BenjellounF, LawrenceP, VerrierB, GeninC, PaulS: Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. J Virol, 2012; 86:13152–13163.
65.
deCampA, HraberP, BailerRT, et al.: Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol, 2014; 88:2489–2507.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
